A Study of IBI363 in Subjects with Advanced Solid Malignancies

This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

Trial Details

NCT ID
NCT06281678
Phase
PHASE2
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • IBI363
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Ocala, Florida, United States|29.1872,-82.14009
  • Plantation, Florida, United States|26.13421,-80.23184
  • Fairway, Kansas, United States|39.02223,-94.6319
  • Dearborn, Michigan, United States|42.32226,-83.17631

Key Eligibility Criteria

  • Subjects have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures…
  • Male or female subjects ≥ 18 years old;
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
  • Anticipated life expectancy of ≥ 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →